Navigation Links
Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Date:7/25/2012

FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated for the treatment of venous leg ulcers.

Venous leg ulcers affect approximately 2.5 million Americans and are associated with impaired circulation most commonly resulting from damaged veins and/or valves. They typically appear as an open lesion, or ulcer, on the lower extremities, are very slow to heal and often reoccur due to the chronic nature of the underlying disease process.

The Phase 2b trial was designed to determine the potential effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection and skin irritation.  The safety profile of the active groups was similar to the vehicle control.

The 24-week open-label extension of this Phase 2b trial was designed to evaluate the status of the target wound (e.g., open, re-opened or healed), as well as the status of the periwound area following the 12-week treatment period. HP802-247 was not administered to patients durin
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
2. Robert Farrell Joins Bionovos Board of Directors
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
7. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
10. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
11. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The announced sales ... the company is looking to expand in non-healthcare areas, ... The healthcare market research firm says that  Siemens is ... Information,s biennial survey of the IVD market , with ... change in its composition would likely affect IVD market ...
(Date:11/26/2014)... PMG Research, Inc. announced today the ... network of sites that provide clinical research services to pharmaceutical ... lives through its partnerships with large physician practices and integrated ... locations in the Southeastern United States and spans over 60 ... board will be held by: Dr. Robert Holmes, MD, ...
(Date:11/26/2014)... The Pittcon marketing department is pleased to ... mobile app, Pittcon 2015 . ... Store for iOS and Android devices and the Kindle ... and after the event. It acts as an all-inclusive ... sessions, Conferee Networking sessions and short courses. , The ...
(Date:11/26/2014)... 26, 2014 2014 Deep Research ... in-depth research report on the Global Palmitic Acid ... Palmitic Acid, basic information, including definition, classification, application, ... news analysis, etc. , For international and ... Acid market in China and other countries ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Pittcon Releases 2015 Mobile App 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3
... CAMBRIDGE, Mass., April 17, 2012 Inspiration Biopharmaceuticals, Inc. ... Application (BLA) to the U.S. Food and Drug Administration ... factor IX (rFIX) protein for the treatment and prevention ... Based on the terms of its agreement with ...
... OLDSMAR, Fla., April 16, 2012  Cryo-Cell International, Inc. ... world,s first private cord blood bank to separate and ... the first quarter ended February 29, 2012.   ... many changes that are taking place at the Company," ...
... Md., April 16, 2012  The Maryland Technology Enterprise ... University of Maryland $75K Business Plan Competition ... has spurred the commercialization of university technologies and ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) ...
Cached Biology Technology:Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 2Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 3Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B 4Cryo-Cell Reports Financial Results for First Quarter 2012 2Cryo-Cell Reports Financial Results for First Quarter 2012 3Cryo-Cell Reports Financial Results for First Quarter 2012 491 EnTERPreneurs Enter, Nine Remain 291 EnTERPreneurs Enter, Nine Remain 391 EnTERPreneurs Enter, Nine Remain 4
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... National Park in northwest India, one thing was hard for biologist ... jackals. It was the squawks of peacocks in the throes of ... could hear a loud two-part whoop, the distinctive call that male ... a male announces that he,s ready to make his move by ...
... many different types of chemicals and plastics for the ... these materials are provided from petrochemical industry, using fossil ... concerns on the environmental problems and fossil resource availability, ... and materials from renewable non-food biomass through biorefineries. For ...
... Cancer Center study in this month,s edition of the ... potential treatment for melanoma, the most dangerous form of skin ... are expressed and which stay silent. Melanoma tends to lack ... a double negative," says Yiqun Shellman, PhD, investigator at the ...
Cached Biology News:Peacock love songs lure eavesdropping females from afar 2Production of 5-aminovaleric and glutaric acid by metabolically engineered microorganism 2Serendipity points to new potential target and therapy for melanoma 2